Study Regarding the Incidence of Anti-platelet Factor 4-antibodies in Patients Aged 18 to 60 Years With Spontaneous or Infection- or Vaccine-associated or Recurrent Venous and/or Arterial Thrombosis

Recruiting now

Conditions studied: Arterial or Venous Thrombosis

In brief

Prospective investigation of the incidence of anti-platelet factor 4 antibodies in suspected immune-associated arterial and/or venous thrombosis

Key facts

Study ID

NCT06650826

Run by

Cardioangiologisches Centrum Bethanien

People needed

200

Starts

2024-07-01

Expected to finish

2027-01-01

Last updated by the study team

2024-10-21

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age between 18-60 years
• Written informed consent of the patient
• Spontaneous arterial and/or venous thrombosis
• infection-associated arterial and/or venous thrombosis within 30 days of infection
• Vaccine-associated arterial and/or venous thrombosis within 30 days of vaccination
• Recurrent arterial or venous thrombosis despite anticoagulant therapy

You may not qualify if…

• Lack of consent of the patient
• Risk-associated venous thromboses (e.g. following surgery, immobilization, plaster cast, fractures or sprains)
• Risk-associated arterial thromboses (in the presence of vascular risk factors such e.g. diabetes mellitus, hypercholesterolemia, hypertension, nicotine abuse)
• Thromboses more than 120 days old at the time of blood sampling

Where it is running

• Cardioangiologisches Zentrum Bethanien (CCB) — Frankfurt am Main, Germany (enrolling)
• Deutsches Herzzentrum der Charite (DHZC) — Berlin, Germany

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.